Literature DB >> 7008643

The efficacy of Domperidone (R 33812) in the treatment of postoperative vomiting. A double-blind study with a placebo.

L van Leeuwen, J H Helmers.   

Abstract

One hundred patients (14-82 years) were given either domperidone 10 mg I.V. or a placebo after they had vomited postoperatively. The patients were then observed for six hours. A supplementary injection of domperidone 10 mg I.V. from an open supply was given if required. In the placebo group 47.9% of patients needed another injection but only 25% of patients in the domperidone group (p less than 0.01). Vomiting occurred later after domperidone than after the placebo (p less than 0.01). At the end of six hours 74% of patients in the domperidone group had no recurrence of vomiting compared with 38% in the control group. In this study neither vomiting nor the efficacy of domperidone were found to be related to the type of surgery, the type of anaesthetic or the physical status (ASA I-III) of the patient (p greater than 0.05).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7008643

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  3 in total

Review 1.  Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

2.  Systematic review on the recurrence of postoperative nausea and vomiting after a first episode in the recovery room - implications for the treatment of PONV and related clinical trials.

Authors:  Leopold H J Eberhart; Silke Frank; Henning Lange; Astrid M Morin; André Scherag; Hinnerk Wulf; Peter Kranke
Journal:  BMC Anesthesiol       Date:  2006-12-13       Impact factor: 2.217

3.  Treatment of established postoperative nausea and vomiting: a quantitative systematic review.

Authors:  Faranak Kazemi-Kjellberg; Iris Henzi; Martin R Tramèr
Journal:  BMC Anesthesiol       Date:  2001       Impact factor: 2.217

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.